

www.ascept-paganz.com



AUSTRALASIAN SOCIETY OF CLINICAL AND EXPERIMENTAL
PHARMACOLOGISTS AND TOXICOLOGISTS



**100% PURE
NEW ZEALAND**
newzealand.com

Queenstown, New Zealand
25-29 November 2019

Joint scientific meeting

Shared horizons: Optimising drug response to improve patient outcomes
#ASCEPTPAGANZ2019

Program

Download the ASCEPT-PAGANZ 2019 Scientific Meeting app

The **Event App by EventsAIR** includes everything you need to know about the Joint Scientific Meeting including the program, symposia, speakers, abstracts, social program and venue. Use the app to build your own conference agenda and contact other delegates via the app.

Whether you have an Apple iOS or Android mobile device you can download **The Event App by EventsAIR** via your Apple iTunes or Google play account.

To download the app to your phone or tablet, scan the appropriate QR code below:



Android



Apple



To download to your computer, laptop or other device, enter the following URL: <https://expertevents.eventsair.com/attendeeapp/ascept-paganz-2019/ascept-paganz/>

The first time you open the app, you will need to enter this code: **ascept-paganz**

Then, log in using either your account email address and the password you created OR the PIN emailed to you.

Please opt in when you download the app so that you are able to use all of the interactive features and send messages to other delegates.



Engage with @ASCEPT2019 on Twitter for your chance to win a cash prize

#ASCEPTAGANZ2019 contest – \$200 prize

#ASCEPTAGANZSponsors contest – \$200 prize

#ASCEPTAGANZPhotos contest – \$100 prize

Further information is available at the registration desk or via the meeting app.

Social Media Policy

Meeting attendees must gain approval from a speaker or poster presenter prior to quoting or publishing that individual's specific scientific result on any forum including social media. We respectfully ask that if you attend a presentation where a presenter has communicated that they do not wish to have their presentation commented on in the social media environment that you adhere to this request. If you are presenting preliminary or unpublished data, and do not wish the results to be broadcast, please use the following logo with your presentation asking the audience to refrain from posting your material. It should appear on the title slide or poster, and if you like, any slides you do not want posted or commented on, so that your audience recognises your request.



"I request that my presentation is not recorded, photographed, commented on or posted about on social media or in any other forum."

Thank you.

ARE YOU WONDERING WHAT TO DO NEXT?

Join us and make discoveries leading to new medicines:

- High-impact research
- World-renowned academics
- State-of-the-art facilities
- Industry engagement

Research themes:

- Cardiovascular pharmacology
- Drug design
- Lung health research
- Mechanopharmacology
- Neuropharmacology
- Personalised therapeutics
- Translational pharmacology
- Venom research

**Undergraduate and graduate opportunities
Innovative post-graduate research programs
– including a new 'Enterprise' specialisation**






CONTACT US FOR MORE INFORMATION

Associate Professor James Ziogas
Acting Head of Department
jamesz@unimelb.edu.au
<http://go.unimelb.edu.au/f9tr>

**Department of Pharmacology
and Therapeutics**
School of Biomedical Sciences



Monday 25 November 2019

08:00 – 17:00	Registration desk open	
	7th Floor Pre-Function Space, QT Queenstown	
08:30 – 17:00	Beginner Population Approach workshop (Pharmacometrics)	Intermediate Population Approach workshop (Pharmacometrics)
	Room: Rees room, QT Queenstown	Room: Dart room, QT Queenstown
	Supported by	
	    	
17:00 – 17:45	PAGANZ AGM	
	Room: Rees room, QT Queenstown	
18:00 – 19:30	ASCEPT Board meeting	
	Room: Dart room, QT Queenstown	

Tuesday 26 November 2019

08:00 – 18:00	Registration desk open		
	5th Floor Pre-Function Space, Rydges Lakeland Resort		
08:30 – 12:30	Innovation and impact workshop (09:00 – 12:30)	Pharmacogenomics workshop (10:30 – 12:30)	Clinical Pharmacology workshop - Matters of Dose (08:30 – 12:30)
	Room: Clancy room, Rydges Lakeland Resort	Room: Dart room, QT Queenstown	Room: Rees room, QT Queenstown
	Chair: Prof Kevin Pflieger	Chair: Prof Andrew Somogyi	Chair: Dr Peter Donovan
	  <p>Why are innovation and impact important?</p> <p>How can they be achieved?</p> <p>The workshop will include an introduction to SPARK by Prof Michael Wallach, Director, SPARK Oceania, as well as talks by SPARK Alumni</p> 	<p>10:30 – 10:35 Welcome and introduction Prof Andrew Somogyi, Chair ASCEPT Pharmacogenomics SIG</p> <p>10:35 – 11:15 Application of new tools to understand the genetics of adverse drug reactions Prof Martin Kennedy, Carney Centre for Pharmacogenomics, University of Otago, New Zealand</p> <p>11:15 – 11:40 Precision medicine for type 2 diabetes Assoc Prof Rinki Murphy, University of Auckland, New Zealand</p> <p>11:40-12:15 ECR/student short talks Common CYP2D6, CYP2C9, and CYP2C19 gene variants, health anxiety and neuroticism are not strongly related to self-reported antidepressant side effects Dr Simran Maggo, Carney Centre for Pharmacogenomics, University of Otago, New Zealand</p> <p>Attitudes of healthy volunteers to genetic testing in phase I clinical trials Mr Sebastian Levesque, Adelaide Medical School, University of Adelaide, Australia</p> <p>Starting a new pharmacogenomics testing and reporting service in primary care in New Zealand with integration into practice software Mr Sam Mostafa, My DNA Life, Australia</p> <p>12:15-12:30 Pharmacogenomics SIG AGM</p>	<p>08:30 Welcome and introduction Assoc Prof Matt Doogue, University of Otago, Christchurch</p> <p>Part 1 – The Principles of Dosing</p> <p>08:40 – 09:10 Pharmacokinetic principles and dosing Prof Evan Begg, University of Otago, Christchurch</p> <p>09:10 – 09:40 Choosing the dose Prof Steve Duffull, School of Pharmacy, University of Otago</p> <p>09:40 – 10:10 Dosing patients today Dr Phil Drennan, Royal Prince Alfred Hospital, University of Sydney</p> <p>10:10 – 10:30 Panel Discussion</p> <p>10:30 – 11:00 Comfort break</p> <p>Part 2 – Going Beyond the Label</p> <p>11:00 – 12:30 Group discussion to determine the “optimum” process to dose a selected medicine</p> <p>12:30 – 13:00 Clinical Pharmacology SIG AGM</p>
12:30 – 13:30	Break (delegates to make their own lunch arrangements)		

13:30 – 16:30	Education Forum—Shared our teaching ideas: Optimising pharmacology education to improve student outcomes	Neuropharmacology/Drug Discovery workshop
	Room: Dart room, QT Queenstown	Room: Rees room, QT Queenstown
	Chairs: Lynette Fernandes and Anna-Marie Babey	Chairs: Wendy Imlach and Karen Gregory
	Adaptive e-tutorials Eryn Werry, The University of Sydney, Australia	13:30 – 13:45 New strategies to investigate the CCR2 signalling network using phosphoproteomics Simon Foster, Monash University, Australia
	Using Kahoot to engage students in tutorials Zane Stromberga, Bond University, Australia	13:45 – 14:00 Low intrinsic G protein efficacy can explain the improved side effect profile of novel opioid ligands Arisbel Batista-Gondin, Monash University, Australia
	Using lightboards to convey pathways and signalling Christian Moro, Bond University, Australia	14:00 – 14:15 Mechanistic insights into ligand-directed signalling bias as a class B G protein-coupled receptor – Characterisation of an adrenomedullin alanine library Michael Garejla, University of Auckland, New Zealand
	Technology-enhanced learning in physiology and pharmacology: Virtual, augmented reality, gamification and holograms Christian Moro, Bond University, Australia	14:15 – 14:30 Comfort break
	Development of an ANKI card library for pharmacology foundation learning Slade Matthews, The University of Sydney, Australia	14:30 – 14:45 BRET-based assays to study novel aspects of orexin receptor pharmacology Natasha Dale, University of Western Australia, Australia
	Use of the online quizzing platform PeerWise in pharmacology education Clare Guilding, Newcastle University Medicine Malaysia	14:45 – 15:00 Investigating the specificity of cannabidiol signalling Shivani Sachdev, Macquarie University, Australia
	The use of authentic, industry-focused learning activities to engage pharmacology students Barb Kemp-Harper, Monash University, Australia	15:00 – 15:15 Identification of CXCL17 as a novel endogenous inhibitor of CXCR4 Carl White, University of Nottingham and Harry Perkins Institute of Medical Research, University of Western Australia, Australia
	Discussion of issues in Pharmacology Education: Reimagining pharmacology practicals to large classes	15:15 – 15:30 Comfort break
	ASCEPT Education Forum AGM	15:30 – 15:45 Targeting spinal adenosine receptors to reduce pain signalling India Cowie-Kent, Monash University, Australia
		15:45 – 16:00 Targeted delivery to the liver sinusoidal endothelium using orally administered silver sulfide quantum dots Nick Hunt, The University of Sydney, Australia
		16:00 – 16:15 Investigating the role of the calcium-sensing receptor in airway contraction using mouse precision cut lung slices Jiayin Diao, Monash University, Australia
		16:15 – 16:23 Drug Discovery SIG AGM
		16:23 – 16:30 Neuropharmacology SIG AGM
16:30 – 17:00	Comfort break	
17:00 – 18:00	Conference opening and keynote address	<div>Supported by</div> <div></div>
	Room: Coronet and Remarkables rooms, Rydges Lakeland Resort	
	Chairs: Prof Carl Kirkpatrick and Assoc Prof David Foster	
	Wither mechanism-based modeling of drug action? - 99 Prof Donald Mager, University of Buffalo, USA	
18:00 – 19:30	Welcome reception Reds Bar, Rydges Lakeland Resort	



UNIVERSITY
of
OTAGO
Te Whare Wānanga o Ōtāgo
NEW ZEALAND

Division of Health Sciences
Te Wāhanga Matua Mātau Hauora



UNSW Medicine Postgraduate programs in pharmaceutical medicine

Advance your career in the pharmaceutical industry or make a career change by enrolling in a postgraduate degree in Pharmaceutical Medicine.

Delivered by UNSW Sydney – one of the world's top 50 universities – this is Australasia's leading postgraduate program in pharmaceutical medicine. It produces graduates with the knowledge and skills to make a meaningful contribution to medicines research, development and access, working across the pharmaceutical industry, academic health centres or government with the goal of improving the health and wellbeing of individuals.

For more information please visit
med.unsw.edu.au/pharmaceutical-medicine
or contact
pharm.med@unsw.edu.au

CRICOS Provider Code 00098G

CERTARA[®]

90+% of all novel drugs approved by the FDA were supported by Certara software and/or consulting services over the past 4 years.

Certara is the global leader in advancing modern, efficient drug development.



Learn how Certara
can help you



Bb Bellberry Limited

supporting research and ethics

Join us... our core objective is to improve the welfare of research participants and the quality, efficiency and effectiveness of research in Australia.

Not for Profit

Independent & Streamlined
Science and Ethics Review

NHMRC-Certified
HREC meetings
held weekly

**Health & social
science reviews**

Study submission deadline
every Wednesday

**Electronic application
and review system**

Full-time secretariat
providing support services

**Independent site
monitoring**




Research Ethics Education

Call for more information
or apply online

☎ 08 8361 3222
✉ bellberry@bellberry.com.au
www.bellberry.com.au



Wednesday 27 November 2019

07:30 – 18:00	Registration desk open 5th Floor Pre-Function Space, Rydges Lakeland Resort		
08:00 - 08:45	ASCEPT Rand Medal lecture Room: Coronet and Remarkables rooms Chair: Prof Carl Kirkpatrick Molecular and structural basis of the allosteric control of GPCR phenotype by receptor activity-modifying proteins (RAMPs) - 100 Prof Patrick Sexton, Monash Institute of Pharmaceutical Sciences, Monash University		Supported by  
09:00 - 10:30	Oral presentations 1: Cardiovascular Room: Coronet room Chairs: Prof Rebecca Ritchie and Assoc Prof Chrishan Samuel	Oral presentations 2: Pharmacoepidemiology Room: Von room, QT Chairs: Dr Jenni Ilomaki and Assoc Prof Bridin Murnion	Oral presentations 3: Pharmacometrics and Clinical Pharmacology Supported by  Room: Remarkables room Chairs: Assoc Prof David Foster and Dr Stefanie Hennig
09:00 – 09:15	Both β1- and β2-adrenoceptors mediate arrhythmic contractions, ryanodine receptor channel opening and phosphorylation in human failing hearts: Control by PDE3 - 101 Assoc Prof Peter Molenaar, Queensland University of Technology, Australia	Efficacy and safety of tapentadol immediate release for acute pain: A systematic review and meta-analysis - 107 Miss Xinyi Wang, The University of Sydney, Australia	A population pharmacokinetic model of mycophenolic acid using dual-phase absorption and plasma protein binding - 113 Dr David Metz, The University of Melbourne, Australia

09:15 – 09:30	Characterising prolonged high fat diet as a model of obesity-induced left ventricular diastolic dysfunction in mice - 102 Dr Miles De Blasio, Baker Heart and Diabetes Institute, Australia	Prevalence of adverse drug events and adverse drug reactions in hospital among older patients with dementia: A systematic review - 108 Miss Marissa Sakiris, The University of Sydney, Australia	A population pharmacokinetic model for metformin in patients receiving intermittent haemodialysis - 114 Miss Klarissa Sinnappah, University of Otago, Dunedin, New Zealand
09:30 – 09:45	Mechanisms underlying cognitive impairment during small vessel disease - 103 Dr Michael De Silva, La Trobe University, Australia	Missing data reporting in clinical pharmacy research - 109 Dr Sujita Narayan, The University of Sydney, Australia	External evaluation of published population pharmacokinetic models of tacrolimus in adult heart transplant recipients - 115 Ms Ranita Kirubakaran, University of New South Wales, Australia
09:45 – 10:00	Impact of diabetes on the murine cardiac cellular landscape and systemic leukocyte proportions - 104 Mr Charles Cohen, Baker Heart and Diabetes Institute, Australia	Pharmacological treatment dynamics in people initially prescribed metformin or sulfonylurea for type 2 diabetes - 110 Mr Stephen Wood, Monash University, Australia	Systematic literature review comparing target concentration intervention to therapeutic drug monitoring of vancomycin therapy - 116 Mr Guangda Ma, The University of Auckland, New Zealand
10:00 – 10:15	Effects of long-term polypharmacy and deprescribing on cardiovascular function and cardiac structure in aged mice - 105 Ms Trang Tran, Kolling Institute of Medical Research, The University of Sydney, Australia	Pharmacovigilance study of clozapine in New Zealand using three outcomes databases - 111 Assoc Prof David Reith, University of Otago, New Zealand	Assessing the accuracy of two Bayesian forecasting programs in estimating vancomycin drug exposure - 117 Dr Sophie Stocker, St Vincent's Hospital, Sydney, Australia
10:15 – 10:30	Cardiomyocyte ErbB4 receptor deletion causes rapid-onset cardiac failure in neonatal mice - 106 Dr Melissa Reichelt, The University of Queensland, Australia	Recommendations of pharmacological alternatives for anticholinergic class of medications prescribed to individuals with dementia - 112 Dr Sharmin Bala, University of Otago, New Zealand	Regulatory Pharmacometrics in Australia - 118 Dr Mahipal Sinnollareddy, Therapeutic Goods Administration, Australia
10:30 – 11:10	Morning tea with exhibitors Poster presentations: Clinical Pharmacology, Drug Discovery, Pharmacogenomics		Cardiovascular SIG AGM
	Supported by		Room: Coronet room
			Toxicology SIG AGM
	5th Floor Pre-Function Space		Room: Remarkables room
11:15 – 13:15	Symposium 1: Novel pharmacotherapies for cardiopulmonary and respiratory diseases	Symposium 2: Innovative strategies to optimise medicine use in the older population to improve health outcomes	Symposium 3: Molecular control of G protein-coupled receptor efficacy
	Supported by 		Supported by 
	Room: Coronet room	Room: Von room, QT	Room: Remarkables room
	Chairs: Assoc Prof Barbara Kemp-Harper, Monash University and Prof Ross Vlahos, RMIT University, Australia	Chairs: Dr Tom Polasek, Certara, Australia and Dr Gillian Caughey, University of Adelaide and Royal Adelaide Hospital, Australia	Chairs: Prof Patrick Sexton, Monash University, Australia and Prof Debbie Hay, University of Auckland, New Zealand
11:15 – 11:45	Optimising cyclic GMP signalling for the treatment of pulmonary hypertension - 119 Prof Adrian Hobbs, William Harvey Research Institute, UK	Complexity and clinical implications of multiple chronic conditions and polypharmacy in the older population - 123 Dr Gillian Caughey, University of Adelaide and Royal Adelaide Hospital, Australia	Proximal study of biased agonism at G protein-coupled receptors - 127 Dr Peishen (Elva) Zhao, Monash University, Australia

11:45 – 12:15	Pharmacological therapies to target reactivity and remodelling in cardiopulmonary disease - 120 Dr Jane Bourke, Monash University, Australia	A multi-country network to improve medicine use in people with Dementia: The NeuroGEN Collaboration - 124 Dr Jenni Ilomaki, Monash University, Australia	Unravelling the molecular basis of biased agonism using cryo-EM - 128 Assoc Prof Denise Wootten, Monash University, Australia ThermoFisher SCIENTIFIC
12:15 – 12:45	Novel therapeutic strategies for the treatment of chronic obstructive pulmonary disease - 121 Assoc Prof Chrisan Samuel, Monash University, Australia	Methodological challenges and innovative solutions: Understanding the complexity of pharmacoepidemiological studies in the older population - 125 Prof Olaf Klungel, University of Utrecht, The Netherlands	Structural basis for biased agonist action at the angiotensin II type 1 receptor - 129 Dr Andrew Kruse, Harvard Medical School, USA  Drug Discovery Biology  MONASH University Institute of Pharmaceutical Sciences
12:45 – 13:15	Improving immunotherapy response outcomes for lung cancer patients by developing novel biomarker assays - 122 Prof Steven Bozinovski, RMIT University, Australia	Clinical decision support tools for prescribing in the older population: From qualitative dashboards to quantitative modelling and simulation to enable precision dosing - 126 Dr Tom Polasek, Certara, Australia	Structural and functional insights into GPCR-beta-arrestin interaction and signaling - 130 Dr Arun Shukla, Indian Institute of Technology, India
13:15 – 14:10	Lunch with exhibitors Poster presentations: Clinical Pharmacology, Drug Discovery, Pharmacogenomics 5th Floor Pre-Function Space		
14:15 – 15:45	Oral presentations 4: Urogenital and Gastrointestinal	Oral presentations 5: Clinical Trainee and Clinical Pharmacology	Oral presentations 6: Drug Disposition and Response and Pharmacogenomics
		Supported by  AUSTRALIAN MEDICINES HANDBOOK	Supported by  University of South Australia
	Room: Coronet room	Room: Von room, QT	Room: Remarkables room
	Chairs: Dr Betty Exintaris and Dr Nick Veldhuis	Chairs: Dr Nicholas Farinola and Dr Amanda Gwee	Chairs: Dr Cornelia Landersdorfer and Dr Daniel Barratt
14:15 – 14:30	Synthesis of novel P2X1-purinoreceptor antagonists for use in male contraception - 131 Dr Sab Ventura, Monash University, Australia	Efficacy of endothelin receptor antagonists in patients with the pulmonary arterial hypertension-connective tissue disease subtype: A systematic review and meta-analysis - 137 Dr Senthuran Shivakumar, Flinders Medical Centre, Australia	Activity and potential biomarkers of evofosfamide in patient-derived and cell line xenograft models of head and neck cancer - 143 Dr Stephen Jamieson, University of Auckland, New Zealand
14:30 – 14:45	Exploring allosteric modulation of GPCRs for the treatment of gastrointestinal disorders - 132 Dr Jesse DiCello, Monash University, Australia	Use of cannabinoids to manage behaviour in children with developmental/behavioural disorders - 138 Dr Angela Williams, The University of Queensland, Australia	Effect of CYP2C19 phenotype and physiological differences on the pharmacokinetics of clopidogrel and its metabolites in European and Japanese populations - 144 Dr Janna Duong, GlaxoSmithKline, Australia
14:45 – 15:00	Purinergic P2X7 receptor inhibition protects urothelial cells from acrolein-induced cell death, which is independent of oxidative stress - 133 Miss Zhinoos Taidi, UNSW, Australia	Clinical outcomes and pharmacokinetic-pharmacodynamic target attainment in patients treated with oral flucloxacillin plus probenecid for staphylococcal infections - 139 Dr Philip Drennan, Royal Prince Alfred Hospital, Australia	ADME genes predict cancer patient survival: A comprehensive analysis of 21 different human cancers - 145 Dr Dong Gui Hu, Flinders University, Australia

15:00 – 15:15	Age-related changes in histamine receptor mediated contractions of the urinary bladder - 134 Miss Zane Stromberga, Bond University, Australia	Polypharmacy in palliative care: A retrospective comparison of two explicit deprescribing tools - 140 Dr Richard McNeill, Canterbury District Health Board, Australia	A model to inform in-vivo lignocaine pharmacokinetics from a controlled release device - 146 Dr Jacqueline Hannam, University of Auckland, New Zealand
15:15 – 15:30	The impact of ageing on urinary bladder muscarinic receptor activity - 135 Assoc Prof Christian Moro, Bond University, Australia	Monitoring for valproate toxicity in patients with hypoalbuminemia - 141 Dr Arushi Madan, Royal Brisbane & Women's Hospital, Australia	Assessment of inter-ethnic differences in imatinib dosing regimen using physiologically based pharmacokinetic (PBPK) modelling and simulation - 147 Mr Jeffry Adiwidjaja, The University of Sydney, Australia
15:30 – 15:45	Erianin induces apoptosis and autophagy in human prostate cancer cell - 136 Mr I Gusti Surya C Trapika, The University of Sydney, Australia	Medication adherence in gout: Identifying high-risk patient groups in an Australian clinical setting - 142 Mr Chi Mao, University of New South Wales, Australia	Molecular basis of the reduced enzyme activity associated with the cytochrome P450 2C9*3 (Ile359Leu) variant - 148 Prof John Miners, Flinders University, Australia
15:45 – 16:10	Afternoon tea with exhibitors		Inflammation/Respiratory SIG AGM
	<div>Supported by</div> <div> MONASH University</div> <div> MONASH BIOMEDICINE DISCOVERY INSTITUTE</div>		Room: Von room, QT
			Drug Disposition and Response SIG AGM
	5th Floor Pre-Function Space		Room: Remarkables room
16:15 – 18:15	Certara New Investigator Award		<div>Supported by</div> <div> CERTARA</div>
	Room: Coronet and Remarkables rooms		
	Chair: Prof Carl Kirkpatrick		
16:15 – 16:45	Discovery of novel peptide ligands for orphan G protein-coupled receptors - 149 Dr Simon Foster, Monash University, Australia		
16:45 – 17:15	The roles of aerosolized polymyxins in the treatment of lung infections: A step towards dose optimisation - 150 Dr Yu-Wei (Wayne) Lin, Monash University, Australia		
17:15 – 17:45	Translational toxicovigilance: Preventing drug related harms through legislation and policy - 151 Dr Rose Cairns, The University of Sydney, Australia		
17:45 – 18:15	Gain from pain: Using venomous animals to explore new nociceptive pathways - 152 Dr Samuel Robinson, The University of Queensland, Australia		
18:15 – 18:45	ASCEPT New Zealand AGM		
	Room: Von room, QT		



**MEDICAL AND
HEALTH SCIENCES**
SCHOOL OF MEDICAL SCIENCES


Pharmacy and Pharmacology, University of Auckland - ranked #30 in the world QS World University rankings



douglas
improving lives


**An award-winning
NZ pharmaceutical company**
focused on making a positive
difference in healthcare.

douglas.co.nz



UNSW
SYDNEY | Australia's
Global
University

UNSW Medicine
St Vincent's Clinical School



■ No effect
■ Negative effect
■ Positive effect

The Clinical Pharmacology and Toxicology Department, part of St Vincent's Clinical School UNSW Sydney, was established by Denis Wade in 1970.

We provide leadership in clinical pharmacology, toxicology, therapeutics and quality use of medicines locally, nationally and internationally through our research, teaching and training, advisory roles and collaborations.

We focus on understanding inter-subject variation in response to medicines through high quality clinical research.

Come and join us!
stvcs.med.unsw.edu.au/clinical-pharmacology

CRICOS Provider Code 00098G



MONASH
University

**Monash Institute
of Pharmaceutical
Sciences**

- Drug Discovery Biology
- Medicinal Chemistry
- Drug Candidate Optimisation
- Drug Delivery Disposition and Dynamics
- Medicine Use and Safety

**Proud sponsor of
ASCEPT-PAGANZ 2019**



ASCEPT PAGANZ
Population Approach Group of Australia & New Zealand

AMH
AUSTRALIAN MEDICINES HANDBOOK

**AMH is honoured to attend
the ASCEPT-PAGANZ 2019
Joint Scientific Meeting
and supports the
core objective of
optimising drug
response to improve
patient outcomes.**




www.amh.net.au

Thursday 28 November 2019

07:30 – 17:00	Registration desk open		
	5th Floor Pre-Function Space		
08:00 – 09:30	Oral presentations 7: Inflammation / Respiratory	Oral presentations 8: Drug Discovery	Oral presentations 9: Clinical Pharmacology
	Room: Coronet room	Room: Von room, QT	Room: Remarkables room
	Chairs: Assoc Prof Stavros Selemidis and Dr Simone De Luca	Chairs: Assoc Prof Denise Wootten and Dr Jesse DiCello	Chairs: Assoc Prof Matt Doogue and Dr Catherine Lucas
08:00 – 08:15	Comparison of two mice models of non-alcoholic steatohepatitis - 200 Ms Cheng Peng, The University of Melbourne, Australia	Identification of CXCL17 as an endogenous inhibitor of CXCR4 - 206 Dr Carl White, University of Nottingham, UK; University of Western Australia, Australia	Proteomic analysis of drug metabolising enzymes in extracellular vesicles as potential biomarkers - 212 Dr Madelé van Dyk, Flinders University, Australia
08:15 – 08:30	The role of Transforming Growth Factor β (TGFβ) in the response to Influenza A viral infection - 201 Miss Julia Chitty, Monash University, Australia	One inhibitor, two mechanisms? Evidence for allosteric regulation of the lipid kinase PI3Kα - 207 Dr Jack Flanagan, University of Auckland, New Zealand	Determining the pre-analytical instability of beta-Lactam antibiotics in therapeutic drug monitoring samples - 213 Miss Janni Mortensen, University of Copenhagen, Denmark
08:30 – 08:45	A fresh look at cGMP in innate immune responses - 202 Prof Helen Irving, La Trobe University, Australia	Investigating the role of the calcium-sensing receptor in airway contraction using mouse precision cut lung slices - 208 Miss Jiayin Diao, Monash University, Australia	Efficacy and Safety of opioid analgesics for acute pain conditions: An overview of systematic reviews - 214 Dr Christina Abdel Shaheed, Institute for Musculoskeletal Health; The University of Sydney, Australia
08:45 – 09:00	Effects of prolonged exposure to paracetamol on late gestation rat placenta - 203 Miss Yifan Huang, The University of Melbourne, Australia	New strategies to investigate the CC Chemokine Receptor 2 (CCR2) signalling network using phosphoproteomics - 209 Dr Simon Foster, Monash University, Australia	Inability of current dosing to achieve carboplatin targets in advanced NSCLC: Impact of systemic inflammation on carboplatin PK and outcomes - 215 Assoc Prof Kellie Charles, The University of Sydney, Australia
09:00 – 09:15	Mediators from silica-treated macrophages influence contraction of collagen gels seeded with human lung fibroblasts - 204 Ms Claudia Sim, Biomedicine Discovery Institute; Monash University, Australia	Low intrinsic G protein efficacy can explain the improved side effect profile of novel opioid ligands - 210 Dr Arisbel Batista Gondin, Monash University, Australia	Economic evidence for deprescribing medications: A systematic review - 216 Mr Alexander Clough, The University of Sydney, Australia
09:15 – 09:30	In vivo LPS exposure differentially alters intrapulmonary artery reactivity in mouse precision cut lung slices - 205 Miss Emma Lamanna, Monash University, Australia	Orai channel alterations as a consequence of differentiation in a human neural progenitor cell line - 211 Ms Silke Chalmers, The University of Queensland, Australia	Substance use in patients with dual diagnosis - 217 Dr David Taylor, Eastern Health, Australia
09:45 – 10:15	Early Achievement Award for Women		
	Room: Coronet and Remarkables rooms		
	Chair: Dr Danijela Gnjjidic		
	Mechanistic Insights into the Synergistic Antibacterial Effect of a Polymyxin B - ivacaftor combination Against Cystic Fibrosis Pseudomonas aeruginosa - 218 Dr Elena Schneider-Futschik, The University of Melbourne, Australia		
10:15 – 10:30	ASCEPT launch of Equity, Diversity and Inclusion Policy		
	Room: Coronet and Remarkables rooms		
10:30 – 10:40	Launch morning tea		
10:40 – 11:10	Morning tea with exhibitors Poster presentations: Cardiovascular, Drug Disposition and Response, Toxicology, Neuro- and Behavioural Pharmacology, Education, Inflammation/Respiratory, Pharmacoeconomics, Urogenital and Gastrointestinal		
	5th Floor Pre-Function Space		

11:15 – 13:15	Symposium 4: SGLT2 inhibitors: How good are they really?	Symposium 5: Precision medicine in oncology: Beyond diagnosis	Symposium 6: Drug dosing in children – how to do it better!
		Supported by  MEDICAL AND HEALTH SCIENCES SCHOOL OF MEDICAL SCIENCES	Supported by  Division of Health Sciences Te Wāhanga Matua Mātau Hauora
	Room: Coronet room	Room: Von room, QT	Room: Remarkables room
	Chairs: Dr Jenni Ilomaki, Monash University, Australia and Assoc Prof Matt Doogue, University of Otago, New Zealand	Chairs: Prof Andrew Somogyi, University of Adelaide, Australia and Dr Cornelia Landersdorfer, Monash University, Australia	Chairs: Assoc Prof Noel Cranswick, Royal Children's Hospital, The University of Melbourne, Australia and Prof Jennifer Martin, The University of Newcastle, Australia
11:15 – 11:45	SGLT2 inhibitors: Evidence from observational studies - 219 Prof Olaf Klungel, Utrecht University, The Netherlands	Precision medicine in lung cancer treatment - 223 Prof Mark McKeage, University of Auckland, New Zealand	The principles of dosing, response variability, and dose individualisation challenges in children - 227 Dr Hesham Al-Sallami, University of Otago, New Zealand
11:45 – 12:15	SGLT2 inhibitors: Evidence from RCTs - 220 Dr Ingrid Hopper, Monash University, Australia	Establishment of a therapeutic drug monitoring programme for the treatment of childhood cancer patients in the UK - 224 Prof Gareth Veal, Newcastle University, UK	Dosing antibiotics: Method development in neonates - 228 Dr Amanda Gwee, Royal Children's Hospital, Australia
12:15 – 12:45	Emerging adverse drug reactions related to SGLT2 inhibitors - 221 Dr Jenni Ilomaki, Monash University, Australia	Comparison of target concentration intervention dosing tools for busulfan in children - 225 Dr Stefanie Hennig, The University of Queensland, Australia	Immunosuppressant dosing in children: Learning from children and adults - 229 Dr David Metz, Royal Children's Hospital, Australia
12:45 – 13:15	SGLT2 inhibitors in clinical practice - 222 Assoc Prof Matt Doogue, University of Otago, New Zealand	Predicting severe life-threatening toxicity after fluoropyrimidine drugs - 226 Assoc Prof Nuala Helsby, University of Auckland, New Zealand	Predicting time required for complete drug elimination of Infliximab and Adalimumab from infants exposed in utero: A Bayesian forecasting method - 230 Dr Zheng Liu, University of Newcastle, Australia
13:15 – 14:10	Lunch with exhibitors Poster presentations: Cardiovascular, Drug Disposition and Response, Toxicology, Neuro- and Behavioural Pharmacology, Education, Inflammation/Respiratory, Pharmacoepidemiology, Urogenital and Gastrointestinal		Supported by 
	5th Floor Pre-Function Space		
14:15 – 15:45	Oral presentations 10: Neuro- and Behavioural Pharmacology and Drug Discovery	Oral presentations 11: Education and Toxicology	Oral presentations 12: ASCEPT Garth McQueen Prize
	Room: Coronet room	Room: Von room, QT	Room: Remarkables room
	Chairs: Dr Eryn Werry and Dr Martina Kocan	Chairs: Dr Ian Musgrave and Dr Slade Matthews	Chairs: Dr Wendy Imlach and Dr Jane Carland
14:15 – 14:30	Investigating the effects of OXR1 antagonism on goal-directed decision making - 231 Mr Jeremy Metha, The University of Melbourne, Australia	Responding the WHO 3rd global patient safety challenge: Development of an inter-professional medication safety education programme - 237 Assoc Prof Kellie Charles, The University of Sydney, Australia	Targeting the NLRP3 inflammasome as a novel approach to treat pulmonary hypertension - 243 Mrs Tara Scott, Monash University, Australia

14:30 – 14:45	An evaluation of timed snapshot signalling bias analyses for non-equilibrium systems - 232 Mr Xiao Zhu, University of Otago, New Zealand	The third iteration of a foundational unit in a new Pharmacy curriculum - 238 Dr Betty Exintaris, Monash University, Australia	Influenza A virus provokes maternal vascular dysfunction, inflammation and intrauterine growth restriction - 244 Mr Osezua Oseghale, RMIT University, Australia
14:45 – 15:00	Cigarette smoking cessation does not reverse hippocampal-dependent cognitive impairment in mice - 233 Dr Simone De Luca, RMIT University, Australia	Multiple choice questions: Can they assess application of knowledge in pharmacology teaching - 239 Dr Suong Ngo, The University of Adelaide, Australia	Real-world efficacy and safety outcomes of imatinib treatment in patients with Chronic Myeloid Leukemia: An Australian experience - 245 Miss Josephine Touma, The University of Sydney, Australia
15:00 – 15:15	Investigation of the specificity of cannabidiol signalling Miss Shivani Sachdev, Macquarie University, Australia	Developing techniques to isolate and characterise individual Russell's viper venom peptides and proteins - 240 Ms Rachael Thomas, University of South Australia, Australia	Identifying and prioritising patients at high-risk of medication harm using risk prediction models - 246 Mrs Nazanin Falconer, The University of Queensland, Australia
15:15 – 15:30	Idiosyncratic effects of vigabatrin result from gain-of-function GABAA variants - 235 Prof Mary Chebib, The University of Sydney, Australia	The in vitro neurotoxicity of Indian cobra (Naja naja) venom: Efficacy of antivenom - 241 Mr Tam Huynh, Monash University, Australia	The M2 macrophage-derived chemokine, CCL18 is elevated in hypertension and promotes vascular fibrosis - 247 Miss Mingyu Zhu, Monash University, Australia
15:30 – 15:45	The in vitro biological effects of Cannabichromene enantiomers and analogues - 236 Dr Marina Junqueira Santiago, Macquarie University, Australia	Multitask deep learning for metabolism-aware strain-specific assessment of Ames mutagenicity - 242 Mr Raymond Lui, The University of Sydney, Australia	Chronic cigarette smoke exposure causes cognitive impairment and neuroinflammation in mice - 248 Mr Aleksandar Dobric, RMIT University, Australia
15:45 – 16:10	Afternoon tea with exhibitors		Pharmacoepidemiology SIG AGM
	5th Floor Pre-Function Space		Room: Von room, QT
16:15 – 17:15	Japanese Pharmacological Society keynote address		Supported by 
	Room: Coronet and Remarkables rooms		
	Chair: Prof Carl Kirkpatrick		
	Mesoscopic approaches for brain networks: Pharmaceutical and electroceutical insights - 249 Prof Yuji Ikegaya, The University of Tokyo, Japan		
17:15 – 18:15	ASCEPT AGM		Supported by 
	Room: Coronet and Remarkables rooms		
19:00 – 23:30	Meeting dinner Skyline Queenstown		



**University of
South Australia**

Friday 29 November 2019

08:00 – 12:30	Registration desk open 5th Floor Pre-Function Space		
08:30 – 09:30	British Pharmacological Society keynote address Room: Coronet and Remarkables rooms Chair: Prof Carl Kirkpatrick PBPK-IVIVE: The Trojan Horse that Re-injected Mechanisms Back into Models - 300 Prof Amin Rostami-Hodjegan, University of Manchester, UK		Supported by  THE UNIVERSITY OF SYDNEY
	Morning tea with exhibitors Student poster finalists presentations 5th Floor Pre-Function Space		Supported by  ASPET <small>Transforming Discoveries into Therapies</small>
	Symposium 7: Gout: Moving towards centre stage Supported by St Vincent's Clinical School  Room: Coronet room Chairs: Prof Richard Day and Dr Sophie Stocker, UNSW Sydney, UNSW Medicine St Vincent's Clinical School, Australia		
	Symposium 8: Novel therapies for the treatment of stroke and neurological disorders Room: Von room, QT Chairs: Dr Michael De Silva, La Trobe University, Australia and Dr Simon Foster, Monash University, Australia		
10:30 – 12:30	Symposium 9: Using simulation as a learning tool to develop work place readiness Room: Remarkables room Chairs: Dr Hesham Al-Sallami, University of Otago, New Zealand and Associate Prof Lynette Fernandes, University of Western Australia, Australia		
10:30 – 11:00	Allopurinol at the coal face – can we really get to target with an old drug? - 301 Prof Lisa Stamp, University of Otago, New Zealand	Amnion epithelial cell therapy for stroke: Translation of experimental findings into a Phase I clinical trial - 305 Prof Chris Sobey, La Trobe University, Australia	Using patient simulation in the lecture theatre to introduce “real-life” scenarios - 309 Dr Clare Guilding, Newcastle University Medicine, Malaysia Using simulations to develop proficiency in the application of pharmacokinetic concepts - 310 Dr Cornelia Landersdorfer and Dr David Shackleford, Monash University, Australia
11:00 – 11:30	Model-based dosing in patients with gout: The curious case of allopurinol - 302 Dr Daniel Wright, University of Otago, New Zealand	Tailoring metabotropic glutamate receptor 5 activity with biased allosteric modulators for neurodegenerative disorders - 306 Dr Karen Gregory, Monash University, Australia	Clinical Pharmacology Top Trumps for the gamification of student learning about medicines - 311 Assoc Prof Matt Doogue, Christchurch Hospital and University of Otago, New Zealand
11:30 – 12:00	Off indication medicines and novel strategies with potential to treat gout - 303 Prof Anthony Rodgers, UNSW Sydney, The George Institute for Global Health, UNSW Medicine, Australia	The delta-subunit selective GABAA receptor modulator, DS2, improves stroke recovery via an anti-inflammatory mechanism - 307 Dr Andrew Clarkson, University of Otago, New Zealand	Real-time simulation to help students become more confident and reflective practitioners - 312 Prof Steve Duffull, Otago University, New Zealand Panel discussion
12:00 – 12:30	Strategies to improve outcomes for people with gout: eMed approaches - 304 Prof Richard Day, UNSW Sydney, UNSW Medicine St Vincent's Clinical School, Australia	Molecular pharmacology of Cannabinoid Receptor 2, a promising immunomodulatory target - 308 Dr Natasha Grimsey, University of Auckland, New Zealand	
12:45 – 13:15	Awards and meeting close Room: Coronet and Remarkables rooms Chair: Dr Danijela Gnjidic		
13:15 – 13:45	Lunch 5th Floor Pre-Function Space		



Focusing on technical excellence, complete confidentiality, protocol flexibility and the rapid production of your data

NeuroSolutions Ltd, established in 2001 by Professor David Spanswick is a contract research organisation providing electrophysiological and behavioural research in the field of neuroscience.

Our highly qualified team of scientists deliver preclinical research solutions from the single cell right through to the whole animal tailored precisely to our client's needs.

We work on single fee-for-service contracts right up to multiple member research teams driving forward development programs under FTE agreements or as a working partnership. We incorporate the latest technologies in our pursuit of electrophysiological excellence, providing animal behavioural and molecular biological services of the highest quality in parallel with our electrophysiological expertise.

Find out about the diverse range of bespoke assays NeuroSolutions offers in supporting drug discovery and development www.nsolns.com



NeuroSolutions Ltd., Company Number 04199343
PO Box 3517, Coventry, CV4 7ZS, U.K.

Tel: +44 (0)8454 500 171 Email: info@nsolns.com Web: www.nsolns.com

ASCEPT-APSA JOINT SCIENTIFIC MEETING 2020

VENUE

Crown Perth
Western Australia

DATE

Tuesday 24–Friday 27
November 2020

**GLOBAL
SOLUTIONS
FOR GLOBAL
CHALLENGES**

WWW.ASCEPT-APSA2020.COM



Thank you to our sponsors

Major meeting sponsors



Key meeting sponsors



Speaker sponsors



Meeting contributors



Meeting supporters



Dinner sponsor



Exhibitors only



Conference secretariat



T: +61 7 3848 2100 | E: ascept-paganz@expertevents.com.au
PO Box 351, Hamilton Central, QLD 4007 Australia